ISOFOL

Isofol Medical

Market Cap 721.2M

Isofol Medical is a Swedish biotech company developing Modufolin, a new folate-based therapy used in the treatment of colorectal cancer and as a rescue therapy after high-dose chemotherapy treatment. The company was founded in 2008 through a collaboration between Professor Bengt Gustavsson and Merck & Cie. Isofol Medical is based in Gothenburg and is listed at First North Premier since April 2017.

+ more
0.00
Today
Day High
22.90
22.5
Day Low
22.50
Day Open
22.50
Prev Close
22.50
VWAP
22.6
Volume
3K
Turnover
0.059M
Top Broker
DDB
VWAP
22.9
Avg Volume
13K
Avg Turnover
0.293M
Top Brokers
AVA/MLI
VWAP
23.4
Avg Volume
10K
Avg Turnover
0.233M
Top Brokers
AVA/MLI
VWAP
22.8
Avg Volume
14K
Avg Turnover
0.314M
Top Brokers
AVA/PAS
52 week summary
Price Range
20.0
Last
29.4
Beta
N/A
Market Cap
721.2M
Total Return
-2.6%
Trailing P/E
-11.4
Div Yield
0.0%
Shares Outstanding
32.1M
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -9.3%
Change 12 Months 5.3%
Volume Trend
Average Volume 10 vs 60 Days -71.0%
Price VS
52 Week High -23.5%
50 Day Moving Average -4.0%
200 Day moving Average -7.8%

Add article markers

Compare Isofol Medical to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Anders Rabbe, CEO
  • Sven Erickson, CFO
  • Executive board
  • Jan-Eric Österlund, Chairman of the board
Last updated: 2017-10-21 Source: Redeye
Major Owners Equity Votes
Biofol AB 10.8%
10.8%
Handelsbanken Fonder 8.2%
8.2%
Peak Partners 5.8%
5.8%
Danica Pension 3.5%
3.5%
Swedbank Robur Fonder 3.3%
3.3%
Yield Life Science AB (Publ) 3.1%
3.1%
Rhenman Healthcare Equity L/S 2.5%
2.5%
Svenska Handelsbanken AB for PB 2.5%
2.5%
Urus AB 2.4%
2.4%
AFA Försäkring 2.2%
2.2%
Last updated: 2017-10-21 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
0
0 Sales
0
Last 24 weeks
0 Purchases
0
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 32.5
  •  
  • -6.3
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  •  
  • 52.9%
  • 0.0%
  • -6
  • -2
  • 0.0
  • 2014
  •  
  •  
  • 6
  • 2
  • 0
  • 0
  • 8
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 1
  • 0
  • 9
  •  
  •  
  • 0
  • 4
  • 0
  • 4
  • 0
  • 0
  • 0
  • 4
  • 0
  • 0
  • 5
  • 0
  • 5
  • 9
  • 2014
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2
  • -1
  • 2
  • 2014 Q4
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015
  •  
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 32.5
  •  
  • -7.2
  • 0.0
  • 0.0
  • 0.0
  • -0.9
  • 0.0
  • 0.0
  • 0.0
  •  
  • 16.8%
  • 0.0%
  • -7
  • -6
  • 0.8
  • 2015
  •  
  •  
  • 7
  • 2
  • 0
  • 0
  • 9
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 10
  •  
  •  
  • 0
  • 8
  • 0
  • 8
  • 0
  • 0
  • 0
  • 8
  • 0
  • 0
  • 2
  • 0
  • 2
  • 10
  • 2015
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 4
  • 0
  • 4
  • 2015 Q1
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 8
  • -8
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016
  •  
  • -1,562.5%
  • -1,562.4%
  • 1,157.2%
  • -1,599,375.0%
  • -1,602,675.0%
  • -1,602,725.0%
  •  
  • -1.97
  • -1.97
  • 0.00
  •  
  • 32.5
  •  
  • -392.2
  • 0.0
  • 0.0
  • 0.0
  • -98,059.0
  • 6.1
  • 6.1
  • 0.0
  •  
  • 27.9%
  • 0.0%
  • -392
  • -386
  • 0.0
  • 2016
  •  
  •  
  • 392
  • 4
  • 0
  • 0
  • 396
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 396
  •  
  •  
  • 0
  • 17
  • 0
  • 17
  • 0
  • 0
  • 0
  • 17
  • 0
  • 0
  • 7
  • 0
  • 7
  • 23
  • 2016
  • 0
  • -64
  • 0
  • -64
  • 0
  • -64
  • 0
  • -64
  • 7
  • 0
  • -57
  • 2016 Q1
  • 0
  • -15
  • -15
  • 0
  • 0
  • 0
  • -15
  • 0
  • 0
  • 0
  • -15
  • 0
  • -15
  • 2016 Q2
  • 0
  • -11
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • -11
  • 2016 Q3
  • 0
  • -8
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • -8
  • 2016 Q4
  • 0
  • -31
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • -31
  • 2017 E
  • 2017 E
  • 2017 E
  • 2017 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-10-25 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.

Community Posts

Be the first to write something about this company in the community.

Create new post